VEGFA and Arrhythmia: Overall, monitoring the QT interval, correction of associated QT prolongation risk factors and antiarrhythmic and antithrombotic therapy in cancer patients with VEGF inhibitors-induced arrhythmias requires a dedicated cardio-oncology approach with personalized management for each patient [3].